Skip to main content

Table 2 Parameter estimates

From: A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients

Parameters Units Estimate RSE (%) Bootstrap estimate Bootstrap
95% CI
Population parameters
 Clearance (CL) L/day 0.211 3.5 0.211 0.196 to 0.226
 Central volume of distribution (V1) L 3.46 5.8 3.46 3.09 to 3.83
 Peripheral volume of distribution (V2) L 3.46 5.8 3.46 3.09 to 3.84
 Inter-compartmental clearance (Q) L/day 0.48 < 0.1 0.48 0.48 to 0.48
Covariate effects
 Female gender on CL −0.17 29.1 −0.17 −0.27 to −0.06
 BSA effect on CL 0.97 24.1 0.96 0.48 to 1.45
 Albumin effect on CL −1.34 19.8 −1.33 −1.83 to − 0.86
Between-subject variability
 Clearance (CL) CV% 30.7 9 30.3 24.8 to 35.6
 Residual unexplained variability
 Proportional error CV% 31.8 8 31.8 29.1 to 34.2
  1. Population parameters, covariate effects and between-subject variability according to the final population pharmacokinetic model (Mf). Abbreviations: CL clearance, RSE relative standard error, CV% percentage coefficient of variation, CI confidence interval. The shrinkage of the between-subject variability of clearance and the proportional error was 9.2 and 4%, respectively